Pseudovirions As Vehicles for the Delivery of SiRNA

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2009 Dec 10

PMID 19998056

Citations 12

Authors

Paul E Lund

Ryan C Hunt

Michael M Gottesman

Chava Kimchi-Sarfaty

Affiliations

Soon will be listed here.

Abstract

Over the last two decades, small interfering RNA (siRNA)-mediated gene silencing has quickly become one of the most powerful techniques used to study gene function in vitro and a promising area for new therapeutics. Delivery remains a significant impediment to realizing the therapeutic potential of siRNA, a problem that is also tied to immunogenicity and toxicity. Numerous delivery vehicles have been developed, including some that can be categorized as pseudovirions: these are vectors that are directly derived from viruses but whose viral coding sequences have been eliminated, preventing their classification as viral vectors. Characteristics of the pseudovirions discussed in this review, namely phagemids, HSV amplicons, SV40 in vitro-packaged vectors, influenza virosomes, and HVJ-Envelope vectors, make them attractive for the delivery of siRNA-based therapeutics. Pseudovirions were shown to deliver siRNA effector molecules and bring about RNA interference (RNAi) in various cell types in vitro, and in vivo using immune-deficient and immune-competent mouse models. Levels of silencing were not always determined directly, but the duration of siRNA-induced knockdown lasted at least 3 days. We present examples of the use of pseudovirions for the delivery of synthetic siRNA as well as the delivery and expression of DNA-directed siRNA.

Citing Articles

RNA and Single-Stranded DNA Phages: Unveiling the Promise from the Underexplored World of Viruses.

Nguyen H, Watanabe S, Sharmin S, Kawaguchi T, Tan X, Wannigama D Int J Mol Sci. 2023; 24(23).

PMID: 38069353 PMC: 10707117. DOI: 10.3390/ijms242317029.

The Next Generation of Drug Delivery: Harnessing the Power of Bacteriophages.

Aljabali A, Aljbaly M, Obeid M, Shahcheraghi S, Tambuwala M Methods Mol Biol. 2023; 2738:279-315.

PMID: 37966606 DOI: 10.1007/978-1-0716-3549-0_18.

Bacteriophage Technology and Modern Medicine.

Azam A, Tan X, Veeranarayanan S, Kiga K, Cui L Antibiotics (Basel). 2021; 10(8).

PMID: 34439049 PMC: 8388951. DOI: 10.3390/antibiotics10080999.

Self-assembled Viral Nanoparticles as Targeted Anticancer Vehicles.

Wu Y, Li J, Shin H Biotechnol Bioprocess Eng. 2021; 26(1):25-38.

PMID: 33584104 PMC: 7872722. DOI: 10.1007/s12257-020-0383-0.

Generating FN3-Based Affinity Reagents Through Phage Display.

Gorman K, McGinnis J, Kay B Curr Protoc Chem Biol. 2018; 10(2):e39.

PMID: 29927113 PMC: 6020030. DOI: 10.1002/cpch.39.

References

Zhu X, Meng G, Dickinson B, Li X, Mizoguchi E, Miao L . MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells. J Immunol. 2001; 166(5):3266-76. PMC: 2827247. DOI: 10.4049/jimmunol.166.5.3266. View

Fraefel C, Song S, Lim F, Lang P, Yu L, Wang Y . Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J Virol. 1996; 70(10):7190-7. PMC: 190772. DOI: 10.1128/JVI.70.10.7190-7197.1996. View

Sandalon Z, OPPENHEIM A . Self-assembly and protein-protein interactions between the SV40 capsid proteins produced in insect cells. Virology. 1997; 237(2):414-21. DOI: 10.1006/viro.1997.8796. View

Ohuchi M, Asaoka N, Sakai T, Ohuchi R . Roles of neuraminidase in the initial stage of influenza virus infection. Microbes Infect. 2006; 8(5):1287-93. DOI: 10.1016/j.micinf.2005.12.008. View

Lachmann R . Herpes simplex virus-based vectors. Int J Exp Pathol. 2004; 85(4):177-90. PMC: 2517519. DOI: 10.1111/j.0959-9673.2004.00383.x. View

Kaneda Y, Nakajima T, Nishikawa T, Yamamoto S, Ikegami H, Suzuki N . Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol Ther. 2002; 6(2):219-26. DOI: 10.1006/mthe.2002.0647. View

Kaneda Y, Yamamoto S, Nakajima T . Development of HVJ envelope vector and its application to gene therapy. Adv Genet. 2005; 53:307-32. View

Ochiai H, Kurokawa M, Matsui S, Yamamoto T, Kuroki Y, Kishimoto C . Infection enhancement of influenza A NWS virus in primary murine macrophages by anti-hemagglutinin monoclonal antibody. J Med Virol. 1992; 36(3):217-21. DOI: 10.1002/jmv.1890360312. View

Martin S, Caplen N . Applications of RNA interference in mammalian systems. Annu Rev Genomics Hum Genet. 2007; 8:81-108. DOI: 10.1146/annurev.genom.8.080706.092424. View

10.

Kaneda Y, Iwai K, Uchida T . Increased expression of DNA cointroduced with nuclear protein in adult rat liver. Science. 1989; 243(4889):375-8. DOI: 10.1126/science.2911748. View

11.

Behlke M . Progress towards in vivo use of siRNAs. Mol Ther. 2006; 13(4):644-70. PMC: 7106286. DOI: 10.1016/j.ymthe.2006.01.001. View

12.

Marvin D . Filamentous phage structure, infection and assembly. Curr Opin Struct Biol. 1998; 8(2):150-8. DOI: 10.1016/s0959-440x(98)80032-8. View

13.

Nakanishi A, Nakamura A, Liddington R, Kasamatsu H . Identification of amino acid residues within simian virus 40 capsid proteins Vp1, Vp2, and Vp3 that are required for their interaction and for viral infection. J Virol. 2006; 80(18):8891-8. PMC: 1563927. DOI: 10.1128/JVI.00781-06. View

14.

Kondo R, Feitelson M, Strayer D . Use of SV40 to immunize against hepatitis B surface antigen: implications for the use of SV40 for gene transduction and its use as an immunizing agent. Gene Ther. 1998; 5(5):575-82. DOI: 10.1038/sj.gt.3300623. View

15.

Merril C, Biswas B, Carlton R, Jensen N, Creed G, Zullo S . Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci U S A. 1996; 93(8):3188-92. PMC: 39580. DOI: 10.1073/pnas.93.8.3188. View

16.

Khoury M, Louis-Plence P, Escriou V, Noel D, Largeau C, Cantos C . Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis. Arthritis Rheum. 2006; 54(6):1867-77. DOI: 10.1002/art.21876. View

17.

Nguyen T, Menocal E, Harborth J, Fruehauf J . RNAi therapeutics: an update on delivery. Curr Opin Mol Ther. 2008; 10(2):158-67. View

18.

Botchan M, Stringer J, Mitchison T, Sambrook J . Integration and excision of SV40 DNA from the chromosome of a transformed cell. Cell. 1980; 20(1):143-52. DOI: 10.1016/0092-8674(80)90242-1. View

19.

Aigner A . Delivery systems for the direct application of siRNAs to induce RNA interference (RNAi) in vivo. J Biomed Biotechnol. 2006; 2006(4):71659. PMC: 1559929. DOI: 10.1155/JBB/2006/71659. View

20.

Almeida J, EDWARDS D, Brand C, Heath T . Formation of virosomes from influenza subunits and liposomes. Lancet. 1975; 2(7941):899-901. DOI: 10.1016/s0140-6736(75)92130-3. View